ATE202939T1 - Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie - Google Patents
Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familieInfo
- Publication number
- ATE202939T1 ATE202939T1 AT92912453T AT92912453T ATE202939T1 AT E202939 T1 ATE202939 T1 AT E202939T1 AT 92912453 T AT92912453 T AT 92912453T AT 92912453 T AT92912453 T AT 92912453T AT E202939 T1 ATE202939 T1 AT E202939T1
- Authority
- AT
- Austria
- Prior art keywords
- bdnf
- motor neuron
- members
- neuron diseases
- treating motor
- Prior art date
Links
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 title abstract 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 title abstract 3
- 208000005264 motor neuron disease Diseases 0.000 title abstract 2
- 108010025020 Nerve Growth Factor Proteins 0.000 title 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 abstract 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 abstract 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Physical Water Treatments (AREA)
- Water Treatment By Electricity Or Magnetism (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Water Treatment By Sorption (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72770491A | 1991-07-10 | 1991-07-10 | |
| PCT/US1992/004228 WO1993001300A1 (en) | 1991-07-10 | 1992-05-19 | Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE202939T1 true ATE202939T1 (de) | 2001-07-15 |
Family
ID=24923677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92912453T ATE202939T1 (de) | 1991-07-10 | 1992-05-19 | Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP0593516B1 (de) |
| JP (1) | JPH06509094A (de) |
| CN (1) | CN1065768C (de) |
| AT (1) | ATE202939T1 (de) |
| AU (2) | AU675409B2 (de) |
| CA (1) | CA2113083A1 (de) |
| DE (1) | DE69231930T2 (de) |
| DK (1) | DK0593516T3 (de) |
| ES (1) | ES2157903T3 (de) |
| FI (1) | FI940098A7 (de) |
| GR (1) | GR3036776T3 (de) |
| HU (1) | HUT70275A (de) |
| IE (1) | IE921602A1 (de) |
| IL (1) | IL101928A0 (de) |
| NO (1) | NO940084L (de) |
| PT (1) | PT100501A (de) |
| RU (1) | RU94016525A (de) |
| SK (1) | SK2694A3 (de) |
| WO (1) | WO1993001300A1 (de) |
| ZA (1) | ZA923639B (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993025684A1 (en) * | 1992-06-12 | 1993-12-23 | Regeneron Pharmaceuticals, Inc. | Therapeutic and diagnostic methods based on neurotrophin-4 expression |
| FR2717496B1 (fr) * | 1994-03-18 | 1996-04-12 | Rhone Poulenc Rorer Sa | Virus recombinants, préparation et utilisation en thérapie génique. |
| CN1112215C (zh) * | 1999-12-28 | 2003-06-25 | 潘晓东 | 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途 |
| AU2001259453B2 (en) | 2000-05-05 | 2006-08-31 | Beth Israel Deaconess Medical Center | Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis |
| WO2008156418A1 (en) * | 2007-06-19 | 2008-12-24 | Astrazeneca Ab | A method for screening or diagnosis of postpolio syndrome and fibromyalgia |
| MX2010001395A (es) * | 2007-08-10 | 2010-03-10 | Regeneron Pharma | Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano. |
| WO2014111525A2 (en) | 2013-01-18 | 2014-07-24 | Anaxomics Biotech, Sl | New combination therapies for treating nervous system diseases |
| WO2016210325A1 (en) | 2015-06-26 | 2016-12-29 | C.R. Bard, Inc. | Connector interface for ecg-based catheter positioning system |
| WO2023164311A2 (en) * | 2022-02-28 | 2023-08-31 | Bioincept, Llc | Compositions and methods of treating amyotrophic lateral sclerosis (als) and related disorders |
| GB202303495D0 (en) * | 2023-03-09 | 2023-04-26 | Ucl Business Ltd | Therapy for charcot-marie-tooth disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923696A (en) * | 1987-05-04 | 1990-05-08 | Baylor College Of Medicine | Method to prepare a neurotrophic composition |
| GR1000980B (el) * | 1989-08-30 | 1993-03-31 | Max Planck Gesellschaft | Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο. |
| US5229500A (en) * | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
| IE903130A1 (en) * | 1989-09-15 | 1991-03-27 | Regeneron Pharma | Ciliary neurotrophic factor |
-
1992
- 1992-05-19 RU RU94016525/14A patent/RU94016525A/ru unknown
- 1992-05-19 EP EP92912453A patent/EP0593516B1/de not_active Expired - Lifetime
- 1992-05-19 SK SK26-94A patent/SK2694A3/sk unknown
- 1992-05-19 PT PT100501A patent/PT100501A/pt not_active Application Discontinuation
- 1992-05-19 ZA ZA923639A patent/ZA923639B/xx unknown
- 1992-05-19 DE DE69231930T patent/DE69231930T2/de not_active Expired - Lifetime
- 1992-05-19 WO PCT/US1992/004228 patent/WO1993001300A1/en not_active Ceased
- 1992-05-19 CA CA2113083A patent/CA2113083A1/en not_active Abandoned
- 1992-05-19 AU AU20095/92A patent/AU675409B2/en not_active Ceased
- 1992-05-19 JP JP5502202A patent/JPH06509094A/ja active Pending
- 1992-05-19 EP EP96111711A patent/EP0755682A1/de not_active Withdrawn
- 1992-05-19 ES ES92912453T patent/ES2157903T3/es not_active Expired - Lifetime
- 1992-05-19 HU HU9400063A patent/HUT70275A/hu unknown
- 1992-05-19 CN CN92105070A patent/CN1065768C/zh not_active Expired - Fee Related
- 1992-05-19 AT AT92912453T patent/ATE202939T1/de not_active IP Right Cessation
- 1992-05-19 DK DK92912453T patent/DK0593516T3/da active
- 1992-05-19 IL IL101928A patent/IL101928A0/xx unknown
- 1992-07-01 IE IE160292A patent/IE921602A1/en not_active Application Discontinuation
-
1994
- 1994-01-10 FI FI940098A patent/FI940098A7/fi not_active Application Discontinuation
- 1994-01-10 NO NO940084A patent/NO940084L/no unknown
-
1996
- 1996-11-08 AU AU70676/96A patent/AU7067696A/en not_active Abandoned
-
2001
- 2001-10-03 GR GR20010401637T patent/GR3036776T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9400063D0 (en) | 1994-06-28 |
| IE921602A1 (en) | 1993-01-13 |
| PT100501A (pt) | 1993-09-30 |
| AU2009592A (en) | 1993-02-11 |
| GR3036776T3 (en) | 2002-01-31 |
| RU94016525A (ru) | 1996-06-10 |
| EP0593516A4 (de) | 1995-01-18 |
| NO940084D0 (no) | 1994-01-10 |
| JPH06509094A (ja) | 1994-10-13 |
| AU7067696A (en) | 1997-01-16 |
| SK2694A3 (en) | 1995-02-08 |
| DE69231930T2 (de) | 2002-04-11 |
| AU675409B2 (en) | 1997-02-06 |
| ZA923639B (en) | 1993-02-24 |
| FI940098A7 (fi) | 1994-03-10 |
| CA2113083A1 (en) | 1993-01-21 |
| WO1993001300A1 (en) | 1993-01-21 |
| EP0755682A1 (de) | 1997-01-29 |
| EP0593516A1 (de) | 1994-04-27 |
| NO940084L (no) | 1994-03-08 |
| HUT70275A (en) | 1995-09-28 |
| IL101928A0 (en) | 1992-12-30 |
| EP0593516B1 (de) | 2001-07-11 |
| DE69231930D1 (de) | 2001-08-16 |
| DK0593516T3 (da) | 2001-09-17 |
| CN1065768C (zh) | 2001-05-16 |
| CN1071585A (zh) | 1993-05-05 |
| ES2157903T3 (es) | 2001-09-01 |
| FI940098A0 (fi) | 1994-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69634301D1 (de) | Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf) | |
| ATE202939T1 (de) | Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie | |
| ATE178616T1 (de) | Verfahren zur herstellung von biologisch aktivem protein (z.b. tgf) | |
| DE69524679D1 (de) | Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure | |
| DE3686361D1 (de) | Verwendung von bismuth zur herstellung von medikamenten zur behandlung von magen-darmstoerungen, die von campylobacter polyridis verursacht sind. | |
| DE69428130D1 (de) | Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten | |
| FI108146B (fi) | Biologisesti aktiivisten, neurotrofisten NGF/BDNF-sarjan yhdistelmäproteiinien valmistus | |
| ATE196082T1 (de) | Stickstoffoxyd abgebendes präparat zur behandlung von analen erkrankungen | |
| ATE141505T1 (de) | Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht | |
| DE69109376D1 (de) | Hemmung von Muskelschwund und Proteinabbau von Muskeln bei Säugetieren durch Tetrazyklines. | |
| DE69331605D1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
| DE69203254D1 (de) | Herstellung von Crackkatalysatoren und Crackverfahren mit diesen. | |
| DE69635213D1 (de) | Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen | |
| ATA118995A (de) | Humanes virussicheres monomeres immunglobulin a und verfahren zu seiner herstellung | |
| ATE148628T1 (de) | 5-methylisoxazol-4-carbonsäure-anilide und 2- hydroxyethyliden-cyanoessigsäure-anilide zur behandlung von augenkrankheiten | |
| ATE79254T1 (de) | Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen. | |
| DE68905157D1 (de) | Behandlung einer form und ihre anwendung zum aushaerten von gummi. | |
| NZ221098A (en) | Laminated device for transcuticular application of systemic active substance to leaves | |
| DE69330172D1 (de) | Zusammensetzung für die Behandlung von Fasern, damit behandelte Fasern, und Verfahren zur Behandlung von Fasern mit dieser Zusammensetzung | |
| DE69220939D1 (de) | Gegengift immunsera | |
| DE69109314D1 (de) | Humaner monoklonaler Antikörper und diesen enthaltende Arzneimittelzusammensetzung zur Behandlung von Pseudomonasinfektionen. | |
| ATE56363T1 (de) | Verfahren zur herstellung von keimabgetoeteten oder in ihrer virulenz abgeschwaechten substanzen sowie deren verwendung. | |
| ATE84666T1 (de) | Sichere pestizide harzzusammensetzungen zur bekaempfung von bodenbuertigen krankheiten und verfahren zu deren herstellung. | |
| ATE92757T1 (de) | Verfahren zur verbesserung der ventilation waehrend des schlafes und behandlung von ventilationsabnormalitaeten, die mit dem schlaf verbunden sind. | |
| DE69225712D1 (de) | Plasmalopsychosine und plasmalocerebroside und verfahren zur behandlung von neuronalen erkrankungen mit diesen substanzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EEIH | Change in the person of patent owner | ||
| REN | Ceased due to non-payment of the annual fee |